Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
Death rates within 30 days of discharge were 65% higher in the absence of 30-day follow-up compared with older lupus patients who did receive it, according to Christie M. Bartels, MD, MS, of the University of Wisconsin in Madison, and colleagues.
Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com.
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://bit.ly/3DSNMmL
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.
There are several reports suggesting a link between methotrexate (MTX) use and certain skin cancers, yet these are confounded by a higher risk of skin cancers with inflammatory conditions like rheumatoid arthritis of which MTX is the most common treatment.
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active systemic lupus erythematosus (SLE).
Etanercept was FDA approved for use in pediatric psoriasis (PsO) in 2016 and ustekinumab was similarly approved in 2020. This comparative analysis looks at the risk of serious infections (SIE) requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or methotrexate prior to 2016.
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.
Exercise is known to improve function, pain and quality of life (QOL) in patients with knee osteoarthritis (KOA), but optimal amount of exercise is unknown. The Annals of Internal medicine has reported the results of high-dose versus low-dose exercise therapy demonstrating no benefits from more intense exercise.
Dr. Jack Cush reviews the past week of news on RheumNow.com.
NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.
The 2023 Medscape Survey on Physician burnout ranks rheumatology at #10; which is down from #2 when the survey was last done in 2021.
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.
